LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family
摘要:
Several LY294002-GM heterodimers were synthesized with the intent of modulating their activity in the presence of hsp90 and thereby creating selective inhibitors of PI3K and PI3K-related family. (C) 2001 Elsevier Science Ltd. All rights reserved.
LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family
摘要:
Several LY294002-GM heterodimers were synthesized with the intent of modulating their activity in the presence of hsp90 and thereby creating selective inhibitors of PI3K and PI3K-related family. (C) 2001 Elsevier Science Ltd. All rights reserved.
COMPOSITIONS FOR TREATING CANCER AND METHODS FOR MAKING THE SAME
申请人:The Brigham and Women's Hospital, Inc.
公开号:US20150174263A1
公开(公告)日:2015-06-25
Described herein are compositions and methods relating to chemotherapeutic agent conjugates and the treatment of cancer.
本文描述了与化疗药物结合物和癌症治疗相关的组合物和方法。
Compositions for treating cancer and methods for making the same
申请人:THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
公开号:US10300143B2
公开(公告)日:2019-05-28
Described herein are compositions and methods relating to chemotherapeutic agent conjugates and the treatment of cancer.
本文描述的是与化疗剂共轭物和癌症治疗有关的组合物和方法。
Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma
作者:Bharti Sethi、Virender Kumar、Thilina D. Jayasinghe、Yuxiang Dong、Donald R. Ronning、Haizhen A. Zhong、Donald W. Coulter、Ram I. Mahato
DOI:10.1016/j.jconrel.2022.12.055
日期:2023.2
US9789193B2
申请人:——
公开号:US9789193B2
公开(公告)日:2017-10-17
[EN] COMPOSITIONS FOR TREATING CANCER AND METHODS FOR MAKING THE SAME<br/>[FR] COMPOSITIONS POUR LE TRAITEMENT DU CANCER ET LEURS PROCÉDÉS DE PRÉPARATION
申请人:BRIGHAM & WOMENS HOSPITAL
公开号:WO2013188763A9
公开(公告)日:2014-01-23
[EN] Described herein are compositions and methods relating to chemotherapeutic agent conjugates and the treatment of cancer. [FR] La présente invention concerne des compositions et des procédés relatifs à des conjugués d'agents chimiothérapeutiques et au traitement du cancer.